Selvan Kavin, Abalem Maria F, Lacy Gabrielle D, Vincent Ajoy, Héon Elise
Genetics and Genome Biology (GGB) Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Ophthalmol Ther. 2022 Jun;11(3):1031-1046. doi: 10.1007/s40123-022-00514-x. Epub 2022 Apr 30.
Patient-reported outcome measures (PROMs) are questionnaires that assess health outcomes meaningful to the patient. PROMs have multiple applications, such as supporting clinicians' decision-making for patient care, understanding the impact of disease on patient functioning, and evaluating the efficacy of therapeutics. Though PROMs were developed for various eye conditions, no PROM was tailored to pediatric patients with inherited retinal disease (IRD). Hence, a literature search was conducted using MEDLINE and Embase to identify PROMs potentially relevant to this patient population. This review evaluated selected pediatric PROMs against the US Food and Drug Administration (FDA) guidelines and found restricted use in the context of IRD. As there is a need for PROMs tailored to pediatric patients with IRD, we provide a perspective on applying the International Society for Pharmacoeconomics and Outcomes Research and FDA standards on the development of PROMs specific to IRD.
患者报告结局测量(PROMs)是评估对患者有意义的健康结局的问卷。PROMs有多种应用,例如支持临床医生对患者护理的决策、了解疾病对患者功能的影响以及评估治疗效果。尽管PROMs是针对各种眼部疾病开发的,但没有一种PROM是专门为患有遗传性视网膜疾病(IRD)的儿科患者量身定制的。因此,使用MEDLINE和Embase进行了文献检索,以确定可能与该患者群体相关的PROMs。本综述根据美国食品药品监督管理局(FDA)的指南对选定的儿科PROMs进行了评估,发现在IRD背景下其使用受到限制。由于需要为患有IRD的儿科患者量身定制PROMs,我们就应用国际药物经济学和结局研究学会以及FDA标准来开发针对IRD的PROMs提供了一个观点。